Certolizumab pegol in a heterogeneous population of patients with moderate-to-severe rheumatoid arthritis.

ABSTRACT:

Aim

To determine the efficacy and safety of certolizumab pegol for the treatment of rheumatoid arthritis in a real-world setting.

Materials & methods

Patients with moderate-to-severe rheumatoid arthritis who initiated therapy with certolizumab were followed for 12 weeks. Response was assessed with Disease Activity Score of 28 joints, European Ligue Against Rheumatism criteria and Simplified Disease Activity Index. Predictors of response were analyzed with binary logistic regression models.

Results

Statistically significant decreases in tender and swollen joint counts, laboratory parameters and use of corticosteroids and disease-modifying antirheumatic drugs were found. Disease activity also significantly diminished. Higher Disease Activity Score of 28 joints at baseli

SUBMITTER: Soriano ER 

PROVIDER: S-EPMC5905631 | biostudies-literature | 2018 Apr

REPOSITORIES: biostudies-literature